Q1FY21 results: Aurobindo Pharma net profit increases by 22.81 per cent YoY

Aurobindo Pharma Ltd., manufacturer of generic pharmaceuticals and active pharmaceutical ingredients (API) announced its quarterly results on August 12, 2020. The company posted a consolidated net profit of Rs 780.68 crore for Q1FY21, which increased by 22.81 per cent YoY, as compared to Q1FY20 when it reported Rs 635.68 crore.                                                                                                                                                         

The consolidated net sales reported in Q1FY21 came in at Rs 5,924.78 crore, which increased by 8.82 per cent YoY from Rs 5,444.6 crore in Q1FY20. At EBITDA level, the company stood at Rs 1,257.35 crore in Q1FY21 that increased by 9.68 per cent YoY. For Q1FY20, it posted an EBITDA of Rs 1,146.4 crore.                                                                                                                                                             

EBITDA margin as of Q1FY21 was at 21.22 per cent that increased by 16 bps YoY. The net profit margin in Q1FY21 came in at 13.18 per cent, which increased by 1.50 per cent YoY. The net profit margin in Q1FY20 was at 11.68 per cent.

Formulation revenue for the quarter recorded a growth of 9.2 per cent YoY to Rs 5,144.3 crore and accounted for 86.8 per cent of total revenues. Antiretroviral (ARV) business revenue for June quarter stood at Rs 425.5 crore, which increased by 33.6 per cent YoY and accounted for 7.2 per cent of revenue. In Q1FY21, API business posted revenue of Rs 780.2 crore, which increased by 6.5 per cent YoY and contributed 13.2 per cent to the consolidated revenues. The company also filed three drug master file (DMFs) with USFDA during the quarter.

The share closed with a drop of 1.14 per cent at Rs 934 in today’s session on BSE.